Piedmont Lithium CEO Interview: How to Profit from Rising Lithium Demand

Piedmont Lithium (NASDAQ: PLL) holds a 100% interest in the Piedmont Lithium Project located within the world-class Carolina TinSpodumene Belt (TSB) and along trend to the Hallman Beam and Kings Mountain mines, historically providing most of the western world’s lithium between the 1950s and the 1980s. The TSB has been described as one of the largest lithium provinces in the world and is located approximately 25 miles west of Charlotte, North Carolina.

Genetic Technologies: Growing Pipeline of Next Generation Disease Risk Tests

Genetic Technologies (NASDAQ: GENE) is a diversified molecular diagnostics company. GENE offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company's lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class.

Medalist Diversified REIT: Strong Performance in Southeastern Markets

Medalist Diversified REIT (NASDAQ: MDRR) was founded in 2003 as a private equity company specializing in acquiring, owning, and managing commercial real estate in the Southeast. The Company’s strategy is to focus on value-add and opportunistic commercial real estate which is expected to provide an attractive balance of risk and returns. Medalist utilizes a rigorous, consistent, and replicable process for sourcing and conducting due diligence of acquisitions.

Recruiter.com CEO Interview: Revolutionizing the Recruiting Industry

Oct. 6, 2020

Recruiter.com (OTCQB: RCRT) is a hiring platform for the world’s largest network of recruiters. Recruiter.com empowers businesses to recruit specialized talent faster with virtual teams of recruiters and AI job-matching technology. The Recruiter.com network of over 25,000 small and independent recruiters utilize an innovative web platform, complete with AI-driven job matching, screening and video interviewing (Summer 2020) to recruit talent faster.

BioVie: Preparing Pivotal Phase 2b/3 Clinical Trial

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.

President of Milestone Scientific (NYSE AMERICAN: MLSS) Comments on Premier Health Contract

Milestone Scientific (NYSE American: MLSS) President Arjan Haverhals discusses the importance of the Premier Health contract released today. Milestone Scientific is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications.

OLB Group: Omnichannel Commerce and Payment Solutions for Merchants

The OLB Group (NASDAQ: OLB) is led by a team of seasoned industry executives with extensive experience in payments, ecommerce, and mobile commerce. The Company has developed and deploys a suite of integrated fintech and payment facilitation products and services that is a blend of Shopify (NASDAQ: SHOP) and Square (NYSE: SQ) with added features and benefits.

Esports Entertainment Group: Online Gambling Platform for Rapidly Growing Esports Market

Interview with CEO of Esports Entertainment Group Inc. (NASDAQ: GMBL), a licensed online gambling company with a specific focus on esports wagering and 18+ gaming. Esports Entertainment offers fantasy, pools, fixed odds and exchange style wagering on esports events in a licensed, regulated and secure platform to the global esports audience at vie.gg.

Can-Fite BioPharma: Advanced Clinical Development Targeting Multi-Billion-Dollar Markets

Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH.

Annovis Bio: New Approach to Alzheimer’s in Phase 2 Trials

Headquartered in Berwyn, Pennsylvania, Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and, thereby, improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies.

Tiziana Life Sciences: CEO Update on Spinoff and New COVID-19 Trial

Tiziana Life Sciences (NASDAQ: TLSA) CEO & CSO, Dr. Kunwar Shailubhai, discusses the Company’s planned spinoff of StemPrintER and the launch of its new COVID-19 trial in Brazil. Tiziana is a dual-listed clinical stage company developing targeted therapeutics to transform treatment of liver diseases, inflammatory diseases, and cancer. Our clinical pipeline includes drug assets for Crohn's, and hepatocellular carcinoma.

Lantern Pharma: Applying A.I. to Cancer Drug Development

Lantern Pharma (NASDAQ: LTRN) is a clinical stage biotechnology company focused on innovating the cancer drug development process by rescuing and repositioning drug candidates that others have tried, but failed, to develop and developing new drugs of its own using advanced genomics and artificial intelligence (“AI”). Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures aimed at helping identify patients more likely to respond to our pipeline of cancer therapeutics.